Among the EZH2-inhibiting compounds, small molecule inhibitors of EZH2, GSK-126, PF-06821497, MAK683, CPI-0209, CPI-1205 and DS-3201 have entered into clinical trials, although none of these has been approved for cancer treatment, yet [122]. Here, EZH2 is linked to cancer.